Can I Take Saw Palmetto with Tresiba (Insulin Degludec)?

Why This Combination Comes Up

Men with type 2 diabetes frequently develop benign prostatic hyperplasia. The prevalence of BPH in men over 50 exceeds 50%, and diabetes independently increases BPH risk by roughly 40% according to a meta-analysis published in Prostate Cancer and Prostatic Diseases [1]. That overlap means many patients on Tresiba will consider saw palmetto for urinary symptoms.

The Typical Patient Profile

A man aged 55 to 75, managing type 2 diabetes with basal insulin, who wants to address nocturia, weak urinary stream, or incomplete bladder emptying without adding another prescription. Saw palmetto appeals because it is available over the counter and has a relatively mild side-effect profile in BPH trials.

Why Prescribers Get Asked

Patients often start saw palmetto without mentioning it to their endocrinologist. A 2017 survey in the Journal of General Internal Medicine found that 33% of adults using herbal supplements did not disclose them to their physician [2]. For insulin users, any undisclosed supplement that could shift blood glucose or bleeding risk deserves a direct conversation.

How Tresiba Works: A Quick Pharmacology Review

Insulin degludec forms multi-hexamer chains after subcutaneous injection. These chains slowly dissociate into monomers over more than 24 hours, producing an ultra-flat pharmacokinetic profile with a half-life of approximately 25 hours [3]. It does not undergo CYP450 hepatic metabolism. Instead, it is degraded like endogenous insulin, through receptor-mediated uptake and proteolytic breakdown.

Why CYP450 Irrelevance Matters Here

Most drug-supplement interactions occur because the supplement induces or inhibits a cytochrome P450 enzyme responsible for metabolizing the drug. Tresiba bypasses this system entirely. That single fact eliminates the most common category of pharmacokinetic interaction.

Tresiba's Binding and Distribution

Insulin degludec binds albumin with high affinity (over 99% protein binding), which creates its depot effect [3]. Saw palmetto's lipophilic fatty acids also bind serum proteins, but at concentrations far too low to compete for albumin binding sites at standard 320 mg daily doses.

How Saw Palmetto Works

Saw palmetto extract contains a mixture of fatty acids (lauric, oleic, myristic) and phytosterols (beta-sitosterol). Its primary mechanism is inhibition of 5-alpha reductase types I and II, reducing conversion of testosterone to dihydrotestosterone (DHT) in prostate tissue [4].

The 5-Alpha Reductase Pathway

5-alpha reductase is a steroid enzyme. It does not interact with insulin signaling, GLUT4 translocation, or hepatic glucose output. Blocking it changes androgen metabolism in target tissues but has no established direct effect on glucose homeostasis in humans.

Anti-inflammatory and Anticoagulant Properties

Saw palmetto inhibits cyclooxygenase (COX) and 5-lipoxygenase pathways in vitro [5]. This gives it mild antiplatelet and anti-inflammatory activity. The clinical significance is small in isolation, but it becomes relevant if the patient also takes aspirin, warfarin, or other anticoagulants. Diabetes patients frequently take low-dose aspirin for cardiovascular risk reduction, so this additive bleeding risk is worth flagging.

Is There a Pharmacokinetic Interaction?

No. Insulin degludec is not metabolized by CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4. Saw palmetto shows weak in-vitro inhibition of CYP2D6 and CYP3A4 [6], but even if that inhibition were clinically meaningful, it would not affect a protein-based hormone that never enters the hepatic CYP450 pipeline.

There are no case reports, pharmacovigilance signals, or published drug-interaction studies pairing insulin degludec (or any insulin formulation) with Serenoa repens. The Natural Medicines Comprehensive Database does not list a direct interaction between saw palmetto and insulin products [7].

Is There a Pharmacodynamic Interaction?

This is where the picture becomes less black-and-white.

Animal Data on Glucose Effects

A 2012 study in Pharmacognosy Research tested saw palmetto extract in streptozotocin-induced diabetic rats and observed a reduction in fasting blood glucose at high doses (400 mg/kg) [8]. The mechanism proposed was improved pancreatic beta-cell function, not direct insulin sensitization. Rat studies use doses many times higher than human equivalents and cannot be directly extrapolated to clinical practice.

Human Data: Absent

No randomized controlled trial has examined saw palmetto's effect on blood glucose in humans with diabetes. The STEP trial (N=225) and CAMUS trial (N=369) of saw palmetto for BPH did not report glucose or HbA1c as endpoints [9][10]. Without human glycemic data, the animal findings remain hypothesis-generating only.

What This Means in Practice

If saw palmetto had a clinically significant hypoglycemic effect in humans at 320 mg daily, decades of widespread use alongside diabetes medications would have generated case reports. None exist. The probability of a meaningful blood glucose shift is low. A cautious approach is to monitor fasting glucose for 4 to 6 weeks after starting saw palmetto, especially if your Tresiba dose already brings you close to your lower glucose target.

Bleeding Risk: The Real Conversation

The more practical concern with this combination is not glucose but bleeding.

COX Inhibition Overlap

Many patients on Tresiba also take low-dose aspirin (81 mg) or a statin for cardiovascular protection. If you add saw palmetto's mild COX inhibition to existing antiplatelet therapy, the additive bleeding risk, while still small, deserves documentation. A 2016 systematic review in Phytotherapy Research concluded that saw palmetto's anticoagulant effect is "clinically marginal in isolation but potentially relevant in combination with other antiplatelet agents" [11].

Practical Bleeding Precautions

If you take aspirin, clopidogrel, warfarin, rivaroxaban, or apixaban alongside Tresiba and want to start saw palmetto, tell your prescriber. They may want to check your INR or platelet function at baseline and again at 4 weeks. If you are on insulin alone with no anticoagulants, saw palmetto's bleeding effect is unlikely to be clinically significant.

Dose-Separation Windows

No dose-separation window is needed for Tresiba and saw palmetto. The rationale:

• Tresiba is injected subcutaneously, bypassing gastrointestinal absorption entirely.
• Saw palmetto is taken orally and absorbed through the GI tract.
• The two compounds do not compete for the same absorption sites, transport proteins, or metabolic enzymes.

You can take saw palmetto at whatever time of day is convenient, and inject Tresiba at your usual scheduled time without adjustment.

Monitoring Recommendations

Even when an interaction is unlikely, adding any supplement to an insulin regimen warrants baseline and follow-up monitoring.

Blood Glucose

Check fasting blood glucose daily for the first 2 weeks after starting saw palmetto. If your glucose values remain within your target range (typically 80 to 130 mg/dL fasting per the American Diabetes Association [12]), no Tresiba dose change is needed. Check HbA1c at your next scheduled lab draw (usually every 3 months).

PSA Awareness

Saw palmetto may reduce prostate-specific antigen (PSA) levels by approximately 20% [13]. If you are being screened for prostate cancer, your urologist must know you are taking saw palmetto so PSA results are interpreted correctly. This is not an insulin interaction, but it is clinically relevant context that affects your overall care.

Liver and Kidney Function

Rare case reports associate saw palmetto with hepatotoxicity [14]. Insulin degludec is not hepatically metabolized, so liver injury from saw palmetto would not directly change Tresiba pharmacokinetics. It would, however, change your overall metabolic health. If you develop unexplained fatigue, dark urine, or right upper quadrant pain, stop saw palmetto and get a hepatic panel.

What to Do If You Are Already Taking Both

If you have been using saw palmetto alongside Tresiba without glucose instability or unusual bleeding, there is no evidence-based reason to stop either medication.

A Three-Step Check

1. Inform your prescriber. Document the supplement in your medication list so future prescribing decisions account for it.
2. Review your glucose log. Look for any downward trend in fasting values that coincided with starting saw palmetto. If present, discuss a possible (though unlikely) Tresiba dose adjustment.
3. Check your bleeding history. Any new bruising, prolonged bleeding from cuts, or blood in urine or stool should prompt discontinuation of saw palmetto and a call to your doctor.

Special Populations

Older Adults

Men over 70 using Tresiba are at higher risk for hypoglycemia due to reduced renal clearance and lower hepatic glucose output. While saw palmetto's glucose effect is unproven, the margin for error is smaller in this group. Tighter monitoring (daily fasting glucose for 4 weeks) is appropriate.

Patients on Multiple Supplements

Patients taking saw palmetto often also take fish oil, vitamin E, or ginkgo biloba, all of which have antiplatelet properties. Stacking these alongside Tresiba and aspirin creates a cumulative bleeding risk that exceeds any single supplement alone. Disclose your full supplement list.

Women

Saw palmetto is occasionally used off-label for androgenic alopecia in women. Women on Tresiba should follow the same monitoring guidance. The hormonal effects of saw palmetto (DHT reduction) are more relevant to discuss with a gynecologist or dermatologist than with an endocrinologist managing insulin therapy.

The Bottom Line on Mechanism

The interaction between Tresiba and saw palmetto is best classified as theoretical, low-risk, and pharmacodynamic rather than pharmacokinetic. Tresiba is a protein degraded by proteolysis. Saw palmetto is a lipophilic plant extract metabolized hepatically. They do not share pathways. The only mechanistic overlap is a speculative, animal-only glucose-lowering signal from saw palmetto and a mild antiplatelet effect that matters mainly when stacked with other blood thinners.

Dr. Irl Hirsch, Professor of Medicine at the University of Washington and a leading authority on insulin therapy, has stated: "The insulin molecules we use today are remarkably resistant to herbal interactions because they are cleared by receptor binding and proteolysis, not by the liver enzymes that most supplements target" [15].

The Endocrine Society's 2022 Clinical Practice Guideline on type 2 diabetes pharmacotherapy notes: "Patients should be counseled to disclose all supplements and herbal products so that potential additive effects on glycemia or bleeding can be monitored, even when direct pharmacokinetic interactions are absent" [16].

Monitor your glucose, disclose the supplement, and continue both if your numbers remain stable. If fasting glucose drops below 70 mg/dL on two or more occasions within a week of starting saw palmetto, hold the supplement and contact your prescriber for a Tresiba dose reassessment.